Afficher la notice abrégée

Treatment-resistant depression in a real-world setting: first interim analysis of characteristics, healthcare resource use, and utility values of the fondaMental cohort

dc.rights.licenseopenen_US
dc.contributor.authorYRONDI, Antoine
dc.contributor.authorBENNABI, Djamila
dc.contributor.authorHAFFEN, Emmanuel
dc.contributor.authorQUELARD, Delphine
dc.contributor.authorSAMALIN, Ludovic
dc.contributor.authorMARUANI, Julia
dc.contributor.authorALLAUZE, Etienne
dc.contributor.authorPIERRE, Damien
dc.contributor.authorBOUGEROL, Thierry
dc.contributor.authorCAMUS, Vincent
dc.contributor.authorD'AMATO, Thierry
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorDOUMY, Olivier
dc.contributor.authorHOLTZMANN, Jerome
dc.contributor.authorLANCON, Christophe
dc.contributor.authorMOLIERE, Fanny
dc.contributor.authorMOIRAND, Remi
dc.contributor.authorNIETO, Isabel
dc.contributor.authorRICHIERI, Raphaelle
dc.contributor.authorHORN, Mathilde
dc.contributor.authorSCHMITT, Laurent
dc.contributor.authorSTEPHAN, Florian
dc.contributor.authorGENTY, Jean-Baptiste
dc.contributor.authorVAIVA, Guillaume
dc.contributor.authorWALTER, Michel
dc.contributor.authorCOURTET, Philippe
dc.contributor.authorLEBOYER, Marion
dc.contributor.authorLLORCA, Pierre-Michel
dc.contributor.authorMARGUET, Sophie
dc.contributor.authorDENNIS, Nathalie
dc.contributor.authorSCHAETZ, Dominique
dc.contributor.authorEL-HAGE, Wissam
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorAOUIZERATE, Bruno
dc.date.accessioned2023-05-24T09:33:33Z
dc.date.available2023-05-24T09:33:33Z
dc.date.issued2020-12-10
dc.identifier.issn2076-3425en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182291
dc.description.abstractEnBackground: Major depressive disorder (MDD) is among the most common psychiatric disorders. One-third of patients are usually unresponsive to several lines of treatment. This study aimed to describe the FondaMental French cohort of patients with treatment-resistant depression (TRD) and to estimate utility and healthcare resource use outcomes.Methods: Patients with TRD were evaluated prospectively over four years (baseline, 6, 12, 18, 24, 36 and 48 months) in a real-world clinical setting. Interim analyses focused on the first two consecutive years. Four MDD-related states (major depressive episode (MDE), response, remission, recovery) were defined based on the MADRS (Montgomery-Åsberg depression rating scale) and other clinical events. Health status was assessed with the EuroQol 5 Dimensions 5 Level (EQ-5D-5L) questionnaire. Utility values were estimated as preference measures that the patients assigned to their overall health status.Results: This study was based on 252 patients with TRD. The mean utility value by health state was 0.41, 0.63, 0.80, and 0.90, for MDE, response, remission, and recovery, respectively. At baseline, 59% of patients had an MADRS score of at least 28. Their baseline average utility value was lower compared to the other patients (0.43 versus 0.58, p < 0.001). This significant difference persisted at the following visits. The rate of patients in MDEs having at least one hospitalisation for depression or other reasons than depression was generally higher than that in the other health states.Conclusion: This study documented patterns in healthcare resource consumption, quality of life, and other characteristics in patients with TRD, both globally and by health state and depression severity.
dc.language.isoENen_US
dc.rights.urihttp://creativecommons.org/licenses/by/
dc.subject.enhealthcare resource use
dc.subject.enreal-world
dc.subject.entreatment-resistant depression
dc.subject.enutility
dc.title.enTreatment-resistant depression in a real-world setting: first interim analysis of characteristics, healthcare resource use, and utility values of the fondaMental cohort
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/brainsci10120962en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologie/Psychiatrie et santé mentaleen_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33321879en_US
bordeaux.journalBrain Sciencesen_US
bordeaux.page1-16en_US
bordeaux.volume10en_US
bordeaux.hal.laboratoriesNutriNeuro (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.issue12en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINRAEen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-03177554
hal.version1
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Brain%20Sciences&amp;rft.date=2020-12-10&amp;rft.volume=10&amp;rft.issue=12&amp;rft.spage=1-16&amp;rft.epage=1-16&amp;rft.eissn=2076-3425&amp;rft.issn=2076-3425&amp;rft.au=YRONDI,%20Antoine&amp;BENNABI,%20Djamila&amp;HAFFEN,%20Emmanuel&amp;QUELARD,%20Delphine&amp;SAMALIN,%20Ludovic&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
NutriNeuro_BS_2020_Yrondi.pdf
Taille:
755.9Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée